Overview

TMC114-TiDP3-C176 - A Study in Healthy Volunteers Investigating the Bioequivalence Between Two Commercially Available 400-mg Tablets to One New 800-mg Tablet of Darunavir (DRV) in the Presence of Low-dose Ritonavir Under Fed and Fasted Conditions

Status:
Completed

Trial end date:
2011-05-01

Target enrollment:

Participant gender:

Summary

In this study participants will be given 800 mg darunavir, either as one 800-mg tablet formulation (G002), or as two commercially available 400-mg tablets formulation (F030), to evaluate the effect between both, in the presence of low-dose ritonavir under fasted and fed conditions.

Phase:

Phase 1

Details

Lead Sponsor:

Tibotec Pharmaceuticals, Ireland

Treatments:

Darunavir
Ritonavir